Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains Avalo Therapeutics (NASDAQ:AVTX) with a Overweight and raises the price target from $48 to $60.
Piper Sandler analyst Yasmeen Rahimi maintains Avalo Therapeutics (NASDAQ:AVTX) with a Overweight and raises the price target from $48 to $60.